Skip to main content
Clinical Trials/NCT02509013
NCT02509013
Unknown
Not Applicable

Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease: a Prospective, Multi-center, Hospital-based Study

Peking University First Hospital1 site in 1 country10,000 target enrollmentAugust 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Heart Disease
Sponsor
Peking University First Hospital
Enrollment
10000
Locations
1
Primary Endpoint
prevalence of chronic kidney disease in patients with stable coronary heart disease
Last Updated
9 years ago

Overview

Brief Summary

This is a prospective, multi-center, hospital-based observational study. The aim of the study is to evaluate the prevalence of chronic kidney disease in patients with stable coronar heart disease.

Detailed Description

The primary aim of the study is to evaluate the prevalence of chronic kidney disease(CKD) in patients with stable coronary heart disease. The secondary aims include: 1. To evaluate the awareness of CKD in patients with stable coronary heart disease. 2. To find out risk factors that is associated with CKD in these patients. 3. To evaluate the association between CKD and cardiovascular events during one-year's follow-up. Based on sample size estimation, the plan is to recruit 10000 patients from 100 centers. Patients who participate the study will finish one-year's follow up (0 day, 6 months and 12 months after recruitment). During the baseline visit, patients' demographic characters will be collected, and laboratory tests will be performed for urinalysis, renal function, hepatic function, etc. During the 6 months' follow up, MACE(Major adverse cardiovascular events) will be recorded through phone or face to face interview between investigators and patients. MACE include all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, documented re-hospitalization for unstable angina pectoris, and coronary revascularization (including percutaneous coronary intervention and CABG). During the 12 month's follow up, MACE will be recorded, and laboratory tests will be performed again.

Registry
clinicaltrials.gov
Start Date
August 2015
End Date
December 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yong Huo

Director, Department of Cardiology

Peking University First Hospital

Eligibility Criteria

Inclusion Criteria

  • Age≥18 years.
  • Patients with clinical evidence of stable coronary heart disease, who meet at least one of the following three criterias:
  • a. Stable coronary heart disease with objective evidence of atherosclerosis, either coronary angiography shows ≥50% stenosis of at least one of the coronary main stems or first-level branches, or typical exertional angina pectoris with positive stress tests(ECG stress test, echocardiograph stress test, or stress radionuclide myocardial imaging). b Diagnosed of myocardial infarction at least 3 months before recruitment. c.Coronary revascularization(PCI or CABG) at least 3 months before recruitment.
  • Informed consent signed by patients or legal guardians.
  • Willing to and capable of being followed up for 1 year.

Exclusion Criteria

  • Non-atherosclerotic coronary heart disease
  • Deterioration of heart failure during the past 3 months
  • Exposed to contrast agent during the past one month.
  • History of amputation
  • Pregnancy
  • Female patients in menstrual period(still eligible after menstrual period)
  • Organ failure other than heart failure and kidney failure
  • Comorbid other diseases, and life expectancy \<1 year
  • Considered not fit for the study due to other reasons, including but not restricted to : a. Severe infection; b. Acute kidney injury.

Outcomes

Primary Outcomes

prevalence of chronic kidney disease in patients with stable coronary heart disease

Time Frame: 1 year

After recruitment, urinalysis, urine albumin/creatinine ratio(ACR), and serum creatitine will be tested. Chronic kidney disease is defined as ≥1 of the following abnormalities: 1)estimated GFR\<60ml/min per1.73m2. The eGFR is estimated using the CKD-EPI equation ; 2) Presence of proteinuria. Proteinuria is defined as urine ACR \>30mg/g, or urinalysis showing positive proteinuria.

Secondary Outcomes

  • factors associated with chronic kidney disease in patients with stable coronary heart disease(1 year)
  • the awareness rate of chronic kidney disease in patients with stable coronary heart disease(1 year)
  • the association between CKD and cardiovascular events during one-year's follow-up(2 year)

Study Sites (1)

Loading locations...

Similar Trials